Solara Active PP

Why is Solara Active Pharma Sciences Ltd Partly Paidup falling/rising?

As of 18-Jul, the stock price of Solara Active Pharma Sciences Ltd Partly Paidup is stable at 308.70, with a year-to-date decline of 18.78%. Despite a recent intraday gain of 12.87%, the stock has fallen 35.17% over the past year, indicating a negative long-term trend.

As of 18-Jul, the stock price of Solara Active Pharma Sciences Ltd Partly Paidup is currently stable at 308.70, showing no change (0.00%). Despite this stability, the stock has experienced a significant decline over the year, with a year-to-date (YTD) decrease of 18.78% compared to a decline of 8.30% in the benchmark Sensex. Over the past year, the stock has fallen by 35.17%, while the Sensex has only decreased by 4.99%.<BR><BR>Today, the stock opened with a notable gain of 12.87%, reaching an intraday high of Rs 308.70, which indicates a positive performance relative to its sector, outperforming it by 13.15%. However, the stock has shown erratic trading patterns, having not traded on one day out of the last 20 days, and there has been a decline in investor participation, with delivery volume falling by 14.1% against the 5-day average.<BR><BR>In terms of moving averages, the stock is currently higher than its 5-day and 20-day moving averages but lower than its 50-day, 100-day, and 200-day moving averages, suggesting mixed signals regarding its short-term and long-term performance. Overall, while there was a positive movement today, the stock's long-term trend remains negative, contributing to its overall decline.

Which are the latest news on Solara Active PP?

What does Solara Active PP do?

Solara Active Pharma Sciences Ltd Partly Paidup operates in the Pharmaceuticals & Biotechnology sector as a Micro Cap company with a market cap of INR 370 Cr. It has reported no sales or profits recently, and key financial metrics indicate a lack of earnings and dividends.

Overview:<BR>Solara Active Pharma Sciences Ltd Partly Paidup operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The incorporation year and any status changes are not available, and there are no reported sales or profits for the latest quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 370 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>Industry P/E: N/A<BR>Dividend Yield: 0.00%<BR>Debt Equity: 0.00<BR>Return on Equity: 0.00%<BR>Price to Book: 0.00<BR><BR>Contact Details:<BR>Registrar Address: Not available.

How big is Solara Active PP?

As of 10th June, Solara Active Pharma Sciences Ltd Partly Paidup has a market capitalization of 370.00 Cr, classified as a Micro Cap, with no valid data available for recent net sales, net profit, shareholder's funds, or total assets.

As of 10th June, <BR><BR>Market Cap: Solara Active Pharma Sciences Ltd Partly Paidup has a market capitalization of 370.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid data available for Net Sales and Net Profit for the latest 4 quarters.<BR><BR>Balance Sheet Snapshot: There is no valid data available for the latest annual period regarding Shareholder's Funds and Total Assets.

Who are the peers of the Solara Active PP?

Peers of Solara Active PP include Parmax Pharma, Starsource Multi, Zenith Health, Ortin Global, Colinz Labs, Beryl Drugs, Unjha Formul., Ganga Pharma, and Saroja Pharma In. Parmax Pharma leads in 1-year returns at 48.68%, while Zenith Health has the lowest at -28.79%, and Solara Active PP's return is -13.53%.

Peers: The peers of Solara Active PP are Parmax Pharma, Starsource Multi, Zenith Health, Ortin Global, Colinz Labs, Beryl Drugs, Unjha Formul., Ganga Pharma., and Saroja Pharma In.<BR><BR>Quality Snapshot: Below Average management risk is observed at Parmax Pharma, Zenith Health, Ortin Global, Colinz Labs, Beryl Drugs, and Ganga Pharma., while Average management risk is found at Unjha Formul. and Saroja Pharma In. Starsource Multi does not qualify for management risk assessment. Below Average growth is noted for Parmax Pharma, Zenith Health, Ortin Global, Colinz Labs, Beryl Drugs, Ganga Pharma., and Saroja Pharma In, while Average growth is seen at Unjha Formul. Starsource Multi does not qualify for growth assessment. Good capital structure is present at Zenith Health, Colinz Labs, and Unjha Formul., while the rest have Below Average capital structure.<BR><BR>Return Snapshot: Parmax Pharma has the highest 1-year return at 48.68%, while Zenith Health has the lowest at -28.79%. Solara Active PP's own 1-year return is -13.53%, which is better than Zenith Health but worse than Parmax Pharma. Additionally, Ganga Pharma. and Saroja Pharma In have negative six-month returns.

What is the technical trend for Solara Active PP?

As of June 4, 2025, Solara Active PP shows a neutral trend with a slight bullish inclination due to a mildly bullish weekly MACD and RSI, despite daily moving averages being mildly bearish and no clear trend from Dow Theory and OBV.

As of 4 June 2025, the technical trend for Solara Active PP has changed from mildly bearish to sideways. The weekly MACD is mildly bullish, and the RSI is bullish, indicating some positive momentum in the short term. However, daily moving averages are mildly bearish, suggesting caution. The Bollinger Bands on the weekly chart are also bullish, supporting the upward potential. Dow Theory and OBV show no clear trend in both weekly and monthly time frames, indicating a lack of strong directional movement. Overall, the current stance is neutral with a slight bullish inclination, driven primarily by the weekly MACD and RSI.

How has been the historical performance of the Solara Active PP?

No Data Available for this Stock

When is the next results date for Solara Active PP?

No Upcoming Board Meetings

Has Solara Active PP declared dividend?

No Dividend History Available